Edition:
United States

People: Aegerion Pharmaceuticals Inc (AEGR.O)

AEGR.O on Nasdaq

1.97USD
29 Nov 2016
Change (% chg)

$0.10 (+5.35%)
Prev Close
$1.87
Open
$1.89
Day's High
$2.34
Day's Low
$1.86
Volume
2,168,985
Avg. Vol
--
52-wk High
--
52-wk Low
--

Barer, Sol 

Dr. Sol J. Barer, Ph.D., is an Independent Director of Aegerion Pharmaceuticals, Inc., since May 2011. Dr. Barer has served as a member of our Board of Directors since May 2011. Dr. Barer is currently the Managing Partner of SJBarer Consulting LLC. He previously served in various positions at Celgene Corporation (a biopharmaceutical company focused on the treatment of cancer and inflammatory diseases), including Chairman and Chief Executive Officer from May 2006 until June 2010, Executive Chairman from June 2010 until December 2010 and Non-Executive Chairman from January 2011 until June 2011. Prior to that, he held several other positions within Celgene, including President and Chief Operating Officer. Dr. Barer joined the Celanese Research Company in 1974 and formed the biotechnology group that was subsequently spun out to form Celgene. Dr. Barer currently serves on the Boards of Directors of Amicus Therapeutics (a public biopharmaceutical company focused on the development of novel small molecule drugs for the treatment of genetic diseases), InspireMD, Inc. (a public medical device company focused on the development and commercialization of stent system technology), Medgenics (a public gene therapy company), RestorGenex (a public biopharmaceutical company focusing on dermatology, ocular diseases, and women’s health), Teva Pharmaceuticals (a public pharmaceutical company focused on the production of generic medicines, innovative treatments for disorders of the central nervous system, and respiratory products) and several privately held biotechnology companies. Dr. Barer holds a B.S. degree from Brooklyn College and a Ph.D. degree in Organic Chemistry from Rutgers University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --